22nd Century Group (NASDAQ:XXII – Get Free Report) posted its quarterly earnings results on Monday. The biotechnology company reported ($247.80) earnings per share for the quarter, missing the consensus estimate of ($174.00) by ($73.80), FiscalAI reports. 22nd Century Group had a negative return on equity of 69.37% and a negative net margin of 27.04%. The company had revenue of $4.76 million during the quarter, compared to analysts’ expectations of $8.42 million. During the same quarter in the previous year, the company earned ($0.28) EPS.
22nd Century Group Price Performance
22nd Century Group stock opened at $0.77 on Monday. The stock has a fifty day moving average of $49.18 and a 200 day moving average of $1,678.79. 22nd Century Group has a one year low of $0.72 and a one year high of $20,314.50. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.90 and a current ratio of 2.61. The stock has a market cap of $7,701.00, a PE ratio of -0.00 and a beta of 0.76.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of 22nd Century Group in a research note on Monday, October 26th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company currently has an average rating of “Sell”.
Check Out Our Latest Research Report on 22nd Century Group
22nd Century Group Company Profile
22nd Century Group, Inc. was a biotechnology company focused on developing tobacco products with reduced nicotine content. Its research centered on genetically modified tobacco plants and cigarette formulations designed to lower nicotine exposure and support smoking cessation or harm-reduction efforts. The company’s principal product was VLN cigarettes, which were made with very low nicotine tobacco and marketed as containing substantially less nicotine than conventional cigarettes. 22nd Century also historically developed and commercialized other reduced-nicotine cigarette products, including Quest, and pursued applications of its plant-science technology in the tobacco and cannabinoid sectors.
Read More
- Five stocks we like better than 22nd Century Group
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.
